text: <unk>  is a hydrolytic lysosomal N-terminal tripeptidyl peptidase that is FDA approved for the slowing of the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.   Common adverse reactions include pyrexia, ECG abnormalities, decreased CSF protein, vomiting, seizures, hypersensitivity, increased CSF protein, hematoma, headache, irritability, pleocytosis, device-related infection, bradycardia, feeling jittery, and hypotension.
option_0: Cerliponase alfa
option_1: Alglucosidase alfa
option_2: Pegloticase
option_3: Sebelipase alfa
option_4: Peginesatide
option_5: Vestronidase alfa
option_6: Imiglucerase
option_7: Hydroxyethyl starch